Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

  title={Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.},
  author={Ignace Vergote and Susana Banerjee and Anne-Marie Gerdes and Christi J. van Asperen and Christian Marth and F{\'a}tima Vaz and Isabelle Ray-Coquard and Dominique Stoppa-Lyonnet and Antonio Gonz{\'a}lez-Mart{\'i}n and Jalid Sehouli and Nicoletta Colombo},
  journal={European journal of cancer},

Figures and Tables from this paper

Genetic testing for epithelial ovarian cancer.

Ovarian cancer and BRCA mutation genetic testing: the Brazilian reality

BRCA testing is restricted and not recommended for all ovarian cancer patients from the private health care sector and there is a lack of consensus on testing recommendations and discrepancies between coverage and national guidelines standardizing.

An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer

The recent changes to the practice of multi-gene panel use in breast cancer diagnoses are reviewed, including an update on next generation sequencing, alternative models of genetic testing, considerations when ordering these panel tests, and recommendations for management in identified carriers for a variety of genes.

BRCA germline mutation test for all woman with ovarian cancer?

The authors' regression tree-analysis can represent an innovative approach taking into consideration all main clinical pathological information to select OC patients to be candidated for BRCA test, with a probability higher than 17% to carry a pathogenic mutation.

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

The BRCA1/2 assay should be rapidly introduced in routine laboratory practice as first line testing by using harmonized pipelines based on consensus guidelines and some considerations for incorporating genetic analysis of ovarian tumour samples into the patient pathway and ethical requirements are provided.

How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors

New care pathways for breast, prostate and ovarian cancers are proposed, including tumor genomic testing at initial diagnosis in order to help triage genetic counseling referrals.

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)

This consensus guide represents a collection of technical recommendations to address the detection of BRCA1/2 mutations in the molecular diagnostic testing strategy for OC and provides some references, quality parameters, and genomic tools aimed to standardize and facilitate the clinical genomic diagnosis of OC.

RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

The authors concluded that this test, as the first step in all newly diagnosed OC patients, could statisti-cally significantly increase the identification rate of eligible patients for treatment with PARPis.

Ovarian Cancer: Determining Factors That Influence Referral to Genetics

It is found that women with ovarian cancer continue to be under-referred to cancer genetics; only 59% (95% CI 51-67%) of the study sample had documentation of referral following their diagnosis, which suggests a general unmet need to further educate providers on the importance of referral for genetics evaluation in the context of ovarian cancer.



Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review

IntroductionOne of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mutation in BRCA1 (breast cancer gene 1) or BRCA2. Here we describe the impact of previous

SEOM clinical guidelines in Hereditary Breast and ovarian cancer

BRCA genetic testing in patients with BC and OC may influence their locoregional and systemic treatment and the selection criteria are evolving according to new advances in this field and the clinical utility of genetic testing.

[Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].

Genetic testing for hereditary breast and ovarian cancer syndrome is indicated by a genetic counselor on the basis of personal and family history evaluation, with regards to consensual criteria,

Inherited Mutations in Women With Ovarian Carcinoma.

To determine the frequency and importance of germline mutations in cancer-associated genes in OC, a study population of 1915 women with OC and available germline DNA was identified and mutations were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC).

AGO Austria recommendations for genetic testing of patients with ovarian cancer

The Association of Gynecologic Oncology recommends that testing for a germline mutation in BRCa1 or BRCA2 should be offered to all patients with epithelial ovarian cancer, as a standard guideline for genetic testing of patients with an ovarian carcinoma.

Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort

A personal history of Breast cancer and a family history of breast, ovarian, or uterine/endometrioid cancer were found to predict the presence of pathogenic mutations and the presented prediction test is a useful instrument to identify those women eligible for DNA testing.

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

Mainstream genetic testing is effective, efficient and patient-centred and offers a mechanism for large-scale implementation of BRCA gene testing in cancer patients and could be applied in many other countries and to many other areas of genomic medicine.

The integration of BRCA testing into oncology clinics.

The authors report on the establishment of the extended role of the clinical nurse specialist in consenting women for BRCA testing in routine gynaecology-oncology clinics using the mainstreaming model, the first report of oncology nurses in the BRCa testing pathway.

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

BRCA1 and BRCA2 mutations may be more frequent in general populations than previously thought and may be associated with various types of cancers.